Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Planta Medica|July 16, 2016
Caco-2 Permeability Studies and In Vitro hERG Liability Assessment of Tryptanthrin and IndolinoneEvelyn A Jähne, Daniela E Eigenmann, Fahimeh Moradi-Afrapoli, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|July 8, 2024
Deconvoluting and derisking QRS complex widening to improve cardiac safety profile of novel plasmepsin X antimalarialsAnnie Delaunois, Alvaro Cardenas, Teresa de Haro, et al.
Pharmacology Research & Perspectives|February 7, 2023
Testing the nonclinical Comprehensive In Vitro Proarrhythmia Assay (CiPA) paradigm with an established anti-seizure medication: Levetiracetam case studyAnnie Delaunois, François-Xavier Mathy, Miranda Cornet, et al.
Journal of Pharmacological and Toxicological Methods|May 25, 2020
Unraveling the mechanism and the risk behind seizure liability of lead compounds in a neuroscience projectAnnie Delaunois, Michael V Accardi, Véronique André, et al.
Clinical and Translational Science|February 23, 2021
Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off-label in the first wave of COVID-19Annie Delaunois, Matthew Abernathy, Warren D Anderson, et al.
Nature Genetics|March 4, 2003
Mutations in CLCN2 encoding a voltage-gated chloride channel are associated with idiopathic generalized epilepsiesKarsten Haug, Maike Warnstedt, Alexi K Alekov, et al.
Pageof 3